Cargando…
Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications
Peritonitis is a limiting complication of peritoneal dialysis, which is treated by intraperitoneal administration of antibiotics. Various dosing strategies are recommended for intraperitoneally administered vancomycin, which leads to large differences in intraperitoneal vancomycin exposure. Based on...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222948/ https://www.ncbi.nlm.nih.gov/pubmed/37242636 http://dx.doi.org/10.3390/pharmaceutics15051394 |
_version_ | 1785049822494982144 |
---|---|
author | Hartinger, Jan Miroslav Michaličková, Danica Dvořáčková, Eliška Hronová, Karolína Krekels, Elke H. J. Szonowská, Barbora Bednářová, Vladimíra Benáková, Hana Kroneislová, Gabriela Závora, Jan Tesař, Vladimír Slanař, Ondřej |
author_facet | Hartinger, Jan Miroslav Michaličková, Danica Dvořáčková, Eliška Hronová, Karolína Krekels, Elke H. J. Szonowská, Barbora Bednářová, Vladimíra Benáková, Hana Kroneislová, Gabriela Závora, Jan Tesař, Vladimír Slanař, Ondřej |
author_sort | Hartinger, Jan Miroslav |
collection | PubMed |
description | Peritonitis is a limiting complication of peritoneal dialysis, which is treated by intraperitoneal administration of antibiotics. Various dosing strategies are recommended for intraperitoneally administered vancomycin, which leads to large differences in intraperitoneal vancomycin exposure. Based on data from therapeutic drug monitoring, we developed the first-ever population pharmacokinetic model for intraperitoneally administered vancomycin to evaluate intraperitoneal and plasma exposure after dosing schedules recommended by the International Society for Peritoneal Dialysis. According to our model, currently recommended dosing schedules lead to possible underdosing of a large proportion of patients. To prevent this, we suggest avoiding intermittent intraperitoneal vancomycin administration, and for the continuous dosing regimen, we suggest a loading dose of 20 mg/kg followed by maintenance doses of 50 mg/L in each dwell to improve the intraperitoneal exposure. Vancomycin plasma level measurement on the fifth day of treatment with subsequent dose adjustment would prevent it from reaching toxic levels in the few patients who are susceptible to overdose. |
format | Online Article Text |
id | pubmed-10222948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102229482023-05-28 Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications Hartinger, Jan Miroslav Michaličková, Danica Dvořáčková, Eliška Hronová, Karolína Krekels, Elke H. J. Szonowská, Barbora Bednářová, Vladimíra Benáková, Hana Kroneislová, Gabriela Závora, Jan Tesař, Vladimír Slanař, Ondřej Pharmaceutics Article Peritonitis is a limiting complication of peritoneal dialysis, which is treated by intraperitoneal administration of antibiotics. Various dosing strategies are recommended for intraperitoneally administered vancomycin, which leads to large differences in intraperitoneal vancomycin exposure. Based on data from therapeutic drug monitoring, we developed the first-ever population pharmacokinetic model for intraperitoneally administered vancomycin to evaluate intraperitoneal and plasma exposure after dosing schedules recommended by the International Society for Peritoneal Dialysis. According to our model, currently recommended dosing schedules lead to possible underdosing of a large proportion of patients. To prevent this, we suggest avoiding intermittent intraperitoneal vancomycin administration, and for the continuous dosing regimen, we suggest a loading dose of 20 mg/kg followed by maintenance doses of 50 mg/L in each dwell to improve the intraperitoneal exposure. Vancomycin plasma level measurement on the fifth day of treatment with subsequent dose adjustment would prevent it from reaching toxic levels in the few patients who are susceptible to overdose. MDPI 2023-05-02 /pmc/articles/PMC10222948/ /pubmed/37242636 http://dx.doi.org/10.3390/pharmaceutics15051394 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hartinger, Jan Miroslav Michaličková, Danica Dvořáčková, Eliška Hronová, Karolína Krekels, Elke H. J. Szonowská, Barbora Bednářová, Vladimíra Benáková, Hana Kroneislová, Gabriela Závora, Jan Tesař, Vladimír Slanař, Ondřej Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications |
title | Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications |
title_full | Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications |
title_fullStr | Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications |
title_full_unstemmed | Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications |
title_short | Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications |
title_sort | intraperitoneally administered vancomycin in patients with peritoneal dialysis-associated peritonitis: population pharmacokinetics and dosing implications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222948/ https://www.ncbi.nlm.nih.gov/pubmed/37242636 http://dx.doi.org/10.3390/pharmaceutics15051394 |
work_keys_str_mv | AT hartingerjanmiroslav intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT michalickovadanica intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT dvorackovaeliska intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT hronovakarolina intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT krekelselkehj intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT szonowskabarbora intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT bednarovavladimira intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT benakovahana intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT kroneislovagabriela intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT zavorajan intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT tesarvladimir intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications AT slanarondrej intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications |